ÂÜÀòÂÒÂ×

Kathleen Fanning is President and Chief Executive Officer at Mozart Therapeutics. She brings more than 35 years of leadership experience in both public and private biopharmaceutical companies. Prior to Mozart, she served as President and CEO at Nohla Therapeutics, a clinical-stage cell therapy company. During her tenure at Nohla, her strategic and operational leadership transitioned the company from an academic focus to a fully integrated business. Prior to Nohla, Ms. Fanning was Chief Operating Officer at VentiRx, and played an instrumental role in the strategic collaboration and company acquisition by Celgene. She has held senior leadership roles at Cell Therapeutics Inc., and CellPro Inc. that included Vice President of Business Development and Vice President of Sales and Marketing where she built and led global sales and marketing organizations. She also spent 13 years at Zeneca Pharmaceuticals (now AstraZeneca) holding positions of ascending responsibility across sales, marketing and early commercial development. Ms. Fanning received her B.A. in Zoology from Miami University in Oxford, Ohio. She serves as a Director of Egenesis Bio and Walden Biosciences.